NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

62.81M

Vuru Grade

31.66/100

Current Price

$4.15
+0.05 (+1.22%)

Company Metrics

  • P/E 0
  • P/S 6.56
  • P/B 9.07
  • EPS -2.44
  • Cash ROIC 921.20%
  • Cash Ratio 0.51
  • Dividend 0 / N/A %
  • Avg. Vol. 51,873.00
  • Shares 2.78M
  • Market Cap. 62.81M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals Inc.
MarketWatch - Jul 16, 2010
NovaBay Pharmaceuticals Inc. NYSE MKT: NBY. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
Notable Technical Move: What's Next for NovaBay Pharmaceuticals, Inc. After ...
Chester News - Dec 5, 2016
The stock of NovaBay Pharmaceuticals, Inc. (NBY) formed an up wedge with $4.07 target or 3.00% above today's $3.95 share price.
News NovaBay Pharmaceuticals Inc.NBY
Wall Street Journal - Feb 11, 2011
News NovaBay Pharmaceuticals Inc.NBY. Significant News Only. 12/01/16; Press Release. NovaBay to Present at LD Micro Main Event.
EV in Focus on Shares of NovaBay Pharmaceuticals, Inc. (AMEX:NBY)
Liberty News - Dec 6, 2016
Investors may be checking in on the status of NovaBay Pharmaceuticals, Inc. (AMEX:NBY) shares. The company presently has an EV (Enterprise Value) of 52441).
Stock Buzzer: NovaBay Pharmaceuticals, Inc. Declines Again; Strong Momentum ...
Frisco Fastball - Nov 11, 2016
The stock of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) is a huge mover today! The stock decreased 18.00% or $0.9 on November 11, hitting $4.1.
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) reported Net sales of $3.4 million for 3Q - Benchmark Monitor
NovaBay Pharma (NBY) Announces Quarterly Earnings Results, Misses Estimates By ... - The Cerbat Gem
Equity Focus: Indicator Check on Shares of NovaBay Pharmaceuticals Inc. (NBY)
Yankee Analysts - Dec 6, 2016
Traders studying the charts on NovaBay Pharmaceuticals Inc. (NBY) may be interested in looking at the RSI. In terms of Relative Strength Index, the 14-day RSI is currently sitting at 50.5, the 7-day is 53.44, and the 3-day is spotted at 77.03.
Where Does NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) Have Its Focus This Year?
Scibility Media - Aug 15, 2016
NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) has set for itself many targets to hit before the end of 2016. But there is one that the management of the company has been talking about repeatedly: achieving positive cash flow.
Today's Pattern Alert: Is Major Move Coming For NovaBay Pharmaceuticals, Inc ...
Chester News - Nov 14, 2016
The stock of NovaBay Pharmaceuticals, Inc. (NBY) formed an up wedge with $6.55 target or 51.00% above today's $4.34 share price.
NovaBay Pharma (NBY) Releases Earnings Results, Misses Expectations By $0.18 EPS - BBNS
Despite Recent Market Upturn, This Stock Struggled This Week: NovaBay ...
CSZ News - Dec 4, 2016
NovaBay Pharmaceuticals, Inc. (:NBY) stock has moved in a downward direction over the past week, yielding losses for investors after the elections concluded.
NovaBay Pharmaceuticals, Inc. (NBY) Receives An Update From Brokers - The De Soto Edge
NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results
Business Wire (press release) - Aug 11, 2016
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial results for the three ...
NovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q2 2016 Results ... - Seeking Alpha